newsflow to continue , page-3

absolutely, no one prepared to let them go cheap. upside for ords is huge. also management has put on notice that a revenue modelling document is due for asian operations. this should highlight just how lucrative their three unique products could be in the asthma marketplace.

they have done so many hard yards in research, marketing sales channels that its hard to see management and backers allowing this to stay at these levels much longer. they risk an opportunistic takeover if they dont get the share price up to a higher level soon. all iimo dyor etc etc